Xcout Intel
Glycomine, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Glycomine, Inc. among biopharma companies — ranked by similarity to what Glycomine, Inc. actually does, not by market-cap band.
Subscribe to see Glycomine, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Glycomine, Inc.
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Glycomine, Inc. at a glance
Glycomine, Inc. is a biopharma company headquartered in United States. Its most recent funding round, Series C, raised $115M in April 2025. Xcout tracks 16 named people at Glycomine, Inc., including Steve Axon (CEO).
Glycomine, Inc. leadership
- Steve AxonCEO
- Steven AxonChief Executive Officer
- Geoffrey HirdChief Technology Officer
- Hicham AlaouiChief Scientific Officer
- Peter McWilliamsChief Business Officer
- Rose MarinoChief Medical Officer
10 more named people on record for Glycomine, Inc., with roles, board committees and tenure — see the full roster →
Glycomine, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $115M | 11 named | |
| — | $68M | 11 named | |
| SEC Form D filing | $4.9M | — | |
| Series A | $12M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Glycomine, Inc. competitors
Ranked by semantic similarity — how close each company is to Glycomine, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Drug Discovery
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Similar biopharma company
Scout Bio, Inc. is a veterinary biotechnology company specializing in animal health and advanced gene therapy treatments currently being evaluated in clinical trials.
Drug Discovery
Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.
Drug Discovery
Astria Therapeutics, Inc. is a public biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to developing life-changing therapies for patients.
Drug Discovery
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. The company discovers and develops Anticalin-based drugs designed to address significant medical needs.
Drug Discovery
Omniox, Inc. is an early-stage biopharmaceutical company located in San Francisco, California, focused on developing new medicines for hypoxic diseases.
Drug Discovery
LUCA Science is a pre-clinical stage biotechnology company that develops functional mitochondria as therapeutic agents to treat damaged tissues and organs. The company utilizes a proprietary method to isolate functional mitochondria, combining it with advanced drug delivery and formulation technology to create storable biopharmaceutical agents.
Drug Discovery
Retrotope, Inc. is a drug development company headquartered in Los Altos, California, focused on creating therapeutics for degenerative diseases.
Drug Discovery
MinervaX is a privately held biotechnology company headquartered in Copenhagen, Denmark, pursuing the development of a novel maternal prophylactic vaccine for the prevention of Group B Streptococcus disease.
Drug Discovery
Diagonal Therapeutics is a biotechnology company headquartered in Watertown, Massachusetts, pioneering disease-modifying clustering antibody therapeutics to target the root causes of devastating diseases.
Drug Discovery
Cyllene Therapeutics is a global leader in non-replicating HSV-1 therapeutics headquartered in Paris, France, with additional presence in New York, USA.
Drug Discovery
Kainova Therapeutics, formerly known as Domain Therapeutics, is a clinical-stage biopharmaceutical company headquartered in Montreal, Quebec. The company drives a clinical pipeline of advanced GPCR-modulating therapies to address unmet medical needs.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Glycomine, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Glycomine, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →